BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 19246419)

  • 1. Adherence with adjuvant hormonal therapy for breast cancer.
    Ruddy KJ; Partridge AH
    Ann Oncol; 2009 Mar; 20(3):401-2. PubMed ID: 19246419
    [No Abstract]   [Full Text] [Related]  

  • 2. Adherence to endocrine therapy for breast cancer.
    Chlebowski RT; Geller ML
    Oncology; 2006; 71(1-2):1-9. PubMed ID: 17344666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyond tamoxifen.
    Pritchard KI
    J Clin Oncol; 2005 Aug; 23(22):4850-2. PubMed ID: 16009956
    [No Abstract]   [Full Text] [Related]  

  • 4. Hormonal therapy for breast cancer.
    CA Cancer J Clin; 2005; 55(3):195-8. PubMed ID: 15890641
    [No Abstract]   [Full Text] [Related]  

  • 5. Letrozole compared with tamoxifen as initial adjuvant therapy for breast cancer.
    Buzdar AU
    J Clin Oncol; 2007 May; 25(15):2147-8; author reply 2148. PubMed ID: 17513830
    [No Abstract]   [Full Text] [Related]  

  • 6. The optimal duration of adjuvant hormonal therapy for early-stage breast cancer.
    Winer E
    Clin Adv Hematol Oncol; 2008 Aug; 6(8):573-4. PubMed ID: 18820598
    [No Abstract]   [Full Text] [Related]  

  • 7. [Assessment of the quality of life of women with breast cancer in adjuvant treatment with tamoxifen or aromatase inhibitors--a randomized trial].
    Volovăţ C; Volovăţ SR; Dogaru C; Vulpoi C
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(1):53-7. PubMed ID: 21688560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant aromatase inhibitors for breast cancer.
    Howell A
    Lancet; 2005 Aug 6-12; 366(9484):431-3. PubMed ID: 16084234
    [No Abstract]   [Full Text] [Related]  

  • 9. Advances in adjuvant hormonal therapy for postmenopausal women.
    Strasser-Weippl K; Goss PE
    J Clin Oncol; 2005 Mar; 23(8):1751-9. PubMed ID: 15755983
    [No Abstract]   [Full Text] [Related]  

  • 10. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
    Tuxen MK; Nielsen DL; Lindberg H; Kamby C
    Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant treatment for early breast cancer.
    Smith I
    Ann Oncol; 2005; 16 Suppl 2():ii182-7. PubMed ID: 15958454
    [No Abstract]   [Full Text] [Related]  

  • 12. Which is the appropriate adjuvant endocrine therapy for premenopausal patients with breast cancer?
    Petrelli F; Barni S
    Clin Breast Cancer; 2015 Jun; 15(3):169-70. PubMed ID: 25600162
    [No Abstract]   [Full Text] [Related]  

  • 13. Adherence to long-term adjuvant hormonal therapy for breast cancer.
    Gotay C; Dunn J
    Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):709-15. PubMed ID: 22098287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aromatase inhibitors as adjuvant therapy for breast cancer: overall survival versus disease-free survival as a primary end point in clinical practice.
    Sánchez-Muñoz A; Ribelles N; Márquez A; Pérez-Ruiz E; Alba E
    J Clin Oncol; 2009 Dec; 27(35):e255-6; author reply e257-8. PubMed ID: 19884520
    [No Abstract]   [Full Text] [Related]  

  • 15. Current concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitors.
    Singh Ranger G
    J Clin Pharm Ther; 2005 Aug; 30(4):313-7. PubMed ID: 15985044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hormonal therapy in breast cancer].
    Espinós J; Reyna C; de la Cruz S; Oiler C; Hernández A; Fernández Hidalgo O; Santisteban M; García Foncillas J
    Rev Med Univ Navarra; 2008; 52(1):40-8. PubMed ID: 18578196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of a switch of aromatase inhibitors to another aromatase inhibitor or tamoxifen on musculoskeletal symptoms in breast cancer; Which is the best?
    Altundag K
    J BUON; 2020; 25(4):2132. PubMed ID: 33099971
    [No Abstract]   [Full Text] [Related]  

  • 18. By the way, doctor. Should I switch from tamoxifen to an aromatase inhibitor?
    Robb-Nicholson C
    Harv Womens Health Watch; 2007 Jun; 14(10):8. PubMed ID: 18018318
    [No Abstract]   [Full Text] [Related]  

  • 19. Aromatase inhibitors--extending the benefits of adjuvant therapy beyond tamoxifen.
    Smith IE
    Breast; 2004 Dec; 13 Suppl 1():S3-9. PubMed ID: 15585377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy.
    Hadji P
    Crit Rev Oncol Hematol; 2010 Feb; 73(2):156-66. PubMed ID: 19299162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.